Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Malcolm A. Smith, Oliver A. Hampton, C. Patrick Reynolds, Min H. Kang, John M. Maris, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, Jianrong Wu, Raushan T. Kurmasheva, David A. Wheeler, Peter J. Houghton

Resultado de la investigación: Articlerevisión exhaustiva

64 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673'. En conjunto forman una huella única.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science